WHAT IS A NORMAL CA125 LEVEL

被引:59
作者
ALAGOZ, T [1 ]
BULLER, RE [1 ]
BERMAN, M [1 ]
ANDERSON, B [1 ]
MANETTA, A [1 ]
DISAIA, P [1 ]
机构
[1] UNIV CALIF IRVINE,IRVINE MED CTR,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,ORANGE,CA 92668
关键词
D O I
10.1006/gyno.1994.1093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CA125 is a coelomic epithelial antigen which is widely used to monitor residual disease in patients undergoing chemotherapy for ovarian cancer. Interpretation of serum CA125 levels has been based on a normal value of 35 U/ml which was derived by screening a young, general population of blood donors which included women with intact reproductive systems. This study addresses the issue of what constitutes a normal serum CA125 level following successful surgical therapy for gynecologic malignancy. Three hundred ninety-three CA125 values were measured in 145 patients after an elapsed time of at least 1 year following completion of surgical therapy for early-stage endometrial or cervical adenocarcinoma. All patients were without evidence of recurrent disease. The mean duration of follow-up was 4.3 years with a median of 3.7 years. Sixty-seven percent of the CA125 values were less than 10 U/ml; 95% were less than or equal to 20 U/ml. The median value for this patient population was 7.5 U/ml with a mode of 7.1 U/ml. There was no correlation between patient age and CA125 levels. These data suggest that the normal value for CA125 used for patient follow-up after treatment for gynecologic adenocarcinoma needs to be redefined. Our data support an upper limit of normal of 20 U/ml and encourage further study on the clinical impact of this new definition. (C) 1994 Academic Press, Inc.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 19 条
  • [1] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
    BAST, RC
    KLUG, TL
    STJOHN, E
    JENISON, E
    NILOFF, JM
    LAZARUS, H
    BERKOWITZ, RS
    LEAVITT, T
    GRIFFITHS, CT
    PARKER, L
    ZURAWSKI, VR
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
  • [2] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA
    BAST, RC
    FEENEY, M
    LAZARUS, H
    NADLER, LM
    COLVIN, RB
    KNAPP, RC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) : 1331 - 1337
  • [3] CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS
    BEREK, JS
    KNAPP, RC
    MALKASIAN, GD
    LAVIN, PT
    WHITNEY, C
    NILOFF, JM
    BAST, RC
    [J]. OBSTETRICS AND GYNECOLOGY, 1986, 67 (05) : 685 - 689
  • [4] SERUM CA125 REGRESSION IN EPITHELIAL OVARIAN-CANCER - CORRELATION WITH REASSESSMENT FINDINGS AND SURVIVAL
    BULLER, RE
    BERMAN, ML
    BLOSS, JD
    MANETTA, A
    DISAIA, PJ
    [J]. GYNECOLOGIC ONCOLOGY, 1992, 47 (01) : 87 - 92
  • [5] OVARIAN-CANCER ANTIGEN CA125 - A PROSPECTIVE CLINICAL-ASSESSMENT OF ITS ROLE AS A TUMOR-MARKER
    CANNEY, PA
    MOORE, M
    WILKINSON, PM
    JAMES, RD
    [J]. BRITISH JOURNAL OF CANCER, 1984, 50 (06) : 765 - 769
  • [6] CA-125 - A USEFUL MARKER IN ENDOMETRIAL CARCINOMA
    DUK, JM
    AALDERS, JG
    FLEUREN, GJ
    DEBRUIJN, HWA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (05) : 1097 - 1102
  • [7] DUK JM, 1989, OBSTET GYNECOL, V73, P661
  • [8] THE PROGNOSTIC IMPLICATIONS OF LOW SERUM CA-125 LEVELS PRIOR TO THE 2ND-LOOK OPERATION FOR STAGE-III AND STAGE-IV EPITHELIAL OVARIAN-CANCER
    GALLION, HH
    HUNTER, JE
    VANNAGELL, JR
    AVERETTE, HE
    CAIN, JM
    COPELAND, LJ
    HIGGINS, RV
    HUSSEINZADEH, N
    NAHHAS, WA
    PARTRIDGE, EE
    PURSELL, SH
    [J]. GYNECOLOGIC ONCOLOGY, 1992, 46 (01) : 29 - 32
  • [9] KIVINEN S, 1986, OBSTET GYNECOL, V67, P468
  • [10] KLUG TL, 1984, CANCER RES, V44, P1048